San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of a number of new and unique monoclonal antibodies used for the clinical testing of human immunodeficiency virus (HIV) into its extensive offering of products for in-vitro diagnostic manufacturing and clinical research applications. The HIV P24 275; HIV P24 114; and HIV P24 220.127.116.11.9.4 anti-human monoclonal antibodies have all been expressly designed for use as an integral component within a number of enzyme immunoassay (EIA) testing procedures. As such, their availability is certain to benefit the needs of clinical and medical researchers, as well as manufacturers of diagnostic test kits.
All of these novel monoclonal antibodies are sourced from mice and processed using various chromatographic techniques to a purity level of > 95%. In addition, matched antibody pairs are available (coater/tracer), which greatly aids in product and application development. The antibodies are supplied preservative-free, demonstrate exceptional lot-to-lot consistencies, exceptional specificity claims and feature an outstanding shelf life stability claim of four (4) years from the date of manufacture. The products are available in a standard 1.0mg fill vial, with larger, bulk configurations also being available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and clinical/life-science research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.